NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 900 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Eloralintide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2026-02-10
• Primary completion: 2028-06-01
• Completion: 2028-07-01
• First posted: 2026-02-06
• Last updated: 2026-04-17

Locations

178 sites across 14 countries: United States, Australia, Belgium, Brazil, China, Czechia, India, Israel, Japan, Mexico, Puerto Rico, Romania, Spain, Taiwan

Regulatory

• FDA-regulated drug study